- Home
- MREO vs CCSI Comparison
MREO vs CCSI Comparison
Compare MREO & CCSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- CCSI
- Stock Information
- Founded
- MREO 2015
- CCSI 2021
- Country
- MREO United Kingdom
- CCSI United States
- Employees
- MREO N/A
- CCSI N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- CCSI Retail: Computer Software & Peripheral Equipment
- Sector
- MREO Health Care
- CCSI Technology
- Exchange
- MREO Nasdaq
- CCSI Nasdaq
- Market Cap
- MREO 577.6M
- CCSI 483.6M
- IPO Year
- MREO N/A
- CCSI N/A
- Fundamental
- Price
- MREO $3.68
- CCSI $23.75
- Analyst Decision
- MREO Strong Buy
- CCSI Hold
- Analyst Count
- MREO 4
- CCSI 5
- Target Price
- MREO $7.50
- CCSI $26.00
- AVG Volume (30 Days)
- MREO 769.7K
- CCSI 146.8K
- Earning Date
- MREO 11-12-2024
- CCSI 11-07-2024
- Dividend Yield
- MREO N/A
- CCSI N/A
- EPS Growth
- MREO N/A
- CCSI 16.33
- EPS
- MREO N/A
- CCSI 4.56
- Revenue
- MREO $1,000,000.00
- CCSI $351,153,000.00
- Revenue This Year
- MREO $16.39
- CCSI N/A
- Revenue Next Year
- MREO $9.44
- CCSI N/A
- P/E Ratio
- MREO N/A
- CCSI $5.26
- Revenue Growth
- MREO N/A
- CCSI N/A
- 52 Week Low
- MREO $1.86
- CCSI $11.62
- 52 Week High
- MREO $5.02
- CCSI $28.10
- Technical
- Relative Strength Index (RSI)
- MREO 39.84
- CCSI 50.94
- Support Level
- MREO $3.18
- CCSI $23.05
- Resistance Level
- MREO $4.40
- CCSI $25.91
- Average True Range (ATR)
- MREO 0.24
- CCSI 1.20
- MACD
- MREO -0.06
- CCSI -0.16
- Stochastic Oscillator
- MREO 41.39
- CCSI 21.02
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.